Search by drug, manufacturer, or indication

Displaying 1091 - 1100 of 1165

Nesina (alogliptin)

Status:

Negotiations were not pursued

Manufacturer:

Takeda Canada Inc.

Indication:

Diabetes Mellitus, Type 2

Last updated January 28, 2015

Kazano (alogliptin/metformin)

Status:

Negotiations were not pursued

Manufacturer:

Takeda Canada Inc.

Indication:

Diabetes Mellitus, Type 2

Last updated January 28, 2015

Valtrex (valacyclovir)

Status:

Concluded with an LOI

Manufacturer:

GlaxoSmithKline Inc.

Indication:

Specific Viral Infections

Last updated January 27, 2015

Pomalyst (pomalidomide)

Status:

Concluded with an LOI

Manufacturer:

Celgene Inc.

Indication:

Multiple Myeloma

Last updated January 23, 2015

Adempas (riociguat)

Status:

Concluded with an LOI

Manufacturer:

Bayer Inc.

Indication:

Pulmonary hypertension, chronic thromboembolic

Last updated January 23, 2015

Komboglyze (saxagliptin/metformin)

Status:

Concluded with an LOI

Manufacturer:

AstraZeneca Canada Inc.

Indication:

Diabetes Mellitus, Type 2

Last updated January 9, 2015

Onglyza (saxagliptin)

Status:

Concluded with an LOI

Manufacturer:

AstraZeneca Canada Inc.

Indication:

Diabetes Mellitus, Type 2

Last updated January 9, 2015

Abilify (aripiprazole)

Status:

Negotiations were not pursued

Manufacturer:

Bristol Myers Squibb Canada Inc.

Indication:

Major Depressive Disorder

Last updated December 2, 2014

Picato (ingenol mebutate)

Status:

Negotiations were not pursued

Manufacturer:

LEO Pharma Inc.

Indication:

Actinic keratosis

Last updated December 2, 2014

Stelara (ustekinumab)

Status:

Negotiations were not pursued

Manufacturer:

Janssen Inc.

Indication:

Psoriatic Arthritis

Last updated November 27, 2014